Active ingredient: Umifenovir (Umifenovir) Concentration of active ingredient (mg): 200
Antiviral drug. It specifically inhibits influenza A and B viruses, a coronavirus associated with severe acute respiratory syndrome (SARS-associated coronavirus). The mechanism of antiviral action refers to fusion inhibitors (fusions), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid envelope of the virus and cell membranes. It has a moderate immunomodulatory effect. It has interferon-inducing activity, stimulates humoral and cellular immunity reactions, the phagocytic function of macrophages, increases the body's resistance to viral infections. Reduces the incidence of complications associated with viral infection, as well as exacerbations of chronic bacterial diseases. Therapeutic efficacy in viral infections manifests itself in reducing the severity of general intoxication and clinical phenomena, reducing the duration of the disease. It has a moderate immunomodulating effect. Applies to low-toxic drugs (LD50> 4 g / kg). It does not have any negative effects on the human body when administered orally at recommended doses.
Absorption and distributionQuickly absorbed from the gastrointestinal tract. C max in plasma with the use of umifenovir in a dose of 50 mg is achieved in 1.2 hours, in a dose of 100 mg - 1.5 hours. Umifenovir is rapidly distributed throughout the organs and tissues of the body. Metabolism and elimination Metabolized in the liver. T1 / 2 is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amounts by the kidneys (0.12%). During the first day, 90% of the received dose is eliminated.
Prevention and treatment in adults and children from the age of 12: influenza A and B, other acute respiratory viral infections (including those complicated by bronchitis, pneumonia), severe acute respiratory syndrome (SARS); Complex therapy of acute intestinal infections of rotavirus etiology in children over 12 years old. Combined therapy of chronic bronchitis, pneumonia and recurrent herpes infection. Prevention of postoperative infectious complications.
Hypersensitivity to the drug, age up to 12 years.
Do not exceed recommended doses.
Use during pregnancy and lactation
Data on the use of Arbidol during pregnancy and during breastfeeding is not provided.
Dosage and administration
Inside, before eating. Single dose for adults and children over 12 years old - 200 mg (1 capsule). For non-specific prophylaxis and treatment of influenza and other acute respiratory viral infections: Non-specific prevention of influenza and other acute respiratory viral infections: for non-specific prevention during the epidemic of influenza and other acute respiratory viral infections: 200 mg 2 times a week for 3 weeks. In direct contact with patients with influenza and other acute respiratory viral infections: 200 mg (1 capsule) once a day for 10-14 days. Treatment of influenza and other acute respiratory viral infections: with uncomplicated course: 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days. with the development of oslo neniy (bronchitis, pneumonia, etc.): 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days, then a single dose 1 time a week for 4 weeks. Complex therapy of acute intestinal infections of rotavirus etiology children over 12 years old: 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days. For nonspecific prevention and treatment of severe acute respiratory syndrome (SARS): 200 mg (1 capsule) once a day for 12-14 days.200 mg (1 capsule) 2 times a week for 3 weeks. For treatment of SARS: 200 mg (1 capsule) 2 times a day for 8-10 days. In the complex therapy of chronic bronchitis, pneumonia and herpes infection: 200 mg (1 capsule) 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks. Prevention of postoperative complications: 200 mg (1 capsule) for 2 days before surgery, then 2 and 5 days after surgery.
Rarely - allergic reactions.
Cases of drug overdose are not marked.
Interaction with other drugs
When prescribing with other drugs, no negative effects were noted.
Influence on the ability to drive motor vehicles and control mechanisms. The drug does not show central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy people of various professions requiring increased attention and psychomotor speed (including transport drivers, operators).